BPC-157 Calculator

Also known as: Pentadeca Arginate (analogue)

Healing
Default: 5mg / 2.5mL / 0.25mgAdjust inputs to match your vial
About

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a sequence found in human gastric juice. Animal studies report effects on tendon, ligament, and gastrointestinal tissue repair, but no Phase 3 human trials have been completed. Typical research-protocol dosing is 200–500 µg one to three times daily, subcutaneous or intramuscular. At 5 mg / 2.5 mL (2 mg/mL concentration), a 250 µg dose draws to 12.5 units on a U-100 insulin syringe.

Common vial sizes
2 mglyophilized powder
5 mglyophilized powder
10 mglyophilized powder
Reference dose ranges
0.1 mg≈ 5 U-100 units (at 5mg / 2.5mL)
0.2 mg≈ 10 U-100 units (at 5mg / 2.5mL)
0.25 mg≈ 12.5 U-100 units (at 5mg / 2.5mL)
0.3 mg≈ 15 U-100 units (at 5mg / 2.5mL)
0.5 mg≈ 25 U-100 units (at 5mg / 2.5mL)
Reconstitution

How it's typically prepared

Reconstitute with bacteriostatic water and refrigerate. Most protocols dose by injection close to the site of injury (subcutaneous), though no human pharmacokinetic standard exists.

Dosage

BPC-157 Dosage

Published BPC-157 protocols use 200–500 µg per dose, given one to three times daily. Dose selection in the research literature varies with the application: musculoskeletal-injury studies commonly report 200–250 µg twice daily near the affected site, while gastrointestinal-focused protocols use 250–500 µg once or twice daily, subcutaneously. No randomized human trial has established a clinically validated dose — all protocols derive from animal data and clinician case series, principally the Sikiric et al. body of work.

At the most common research-vendor reconstitution of 5 mg / 2.5 mL (2 mg/mL concentration), a 250 µg dose draws to 12.5 units on a U-100 insulin syringe. A 500 µg dose draws to 25 units at the same concentration. The calculator above accepts any vial size and BAC water volume — adjust the inputs to match your specific vial.

Most reported BPC-157 cycles run 4 to 6 weeks. Some protocols continue at a maintenance frequency of one to two doses per week afterwards; others discontinue and reassess. As with all research peptides, the absence of long-term human safety data means dose, duration, and cycling decisions should be made with a licensed provider familiar with the published literature.

Chart

BPC-157 Dosage Chart

U-100 insulin syringe units for the most common BPC-157 doses, calculated at the standard 5 mg / 2.5 mL reconstitution (2 mg/mL).

100 µg (0.1 mg)5 units · 0.05 mL
200 µg (0.2 mg)10 units · 0.10 mL
250 µg (0.25 mg)12.5 units · 0.125 mL
300 µg (0.3 mg)15 units · 0.15 mL
500 µg (0.5 mg)25 units · 0.25 mL
FAQ

Frequently asked questions

How many units is 250 mcg of BPC-157?
On a U-100 insulin syringe, 250 µg (0.25 mg) of BPC-157 equals 12.5 units when reconstituted at 5 mg / 2.5 mL (2 mg/mL concentration).
What is the BPC-157 dosage in mL on an insulin syringe?
Milliliter dosing depends entirely on the reconstitution concentration. At the standard 5 mg / 2.5 mL (2 mg/mL), a 250 µg dose is 0.125 mL, a 500 µg dose is 0.25 mL, and a 100 µg dose is 0.05 mL. At a 5 mg / 1 mL reconstitution (5 mg/mL — common from research vendors who use less BAC water), divide each volume by 2.5: 250 µg becomes 0.05 mL, 500 µg becomes 0.10 mL. The calculator above converts any vial size and BAC water volume into both mL and U-100 syringe units.
How do I calculate the BPC-157 dose in mL for a 10 mg vial?
A 10 mg BPC-157 vial reconstituted with 5 mL of bacteriostatic water yields a 2 mg/mL concentration — identical to the standard 5 mg / 2.5 mL preparation, so the same mL values apply: 250 µg = 0.125 mL, 500 µg = 0.25 mL. If the same 10 mg vial is reconstituted with 2.5 mL the concentration doubles to 4 mg/mL and the mL values halve: 250 µg becomes 0.0625 mL, which is hard to draw accurately on a U-100 syringe. Most compounding-pharmacy guidance favours reconstitution volumes that keep doses in the 0.1 to 0.25 mL range for measurement accuracy.
Is BPC-157 approved by the FDA?
BPC-157 is not FDA-approved as a drug. Following the February 2026 HHS reclassification, it can be prescribed via licensed compounding pharmacies in the United States. Outside the US it is supplied as a research-grade peptide and is not approved for human use by any major regulator.
What's the difference between BPC-157 and 'Pentadeca Arginate'?
Pentadeca Arginate (PDA) is a closely related arginate-salt analogue of BPC-157, marketed by some compounding pharmacies as more soluble and stable in solution. The amino-acid sequence is the same pentadecapeptide; the difference is the counter-ion. Dose conversions between BPC-157 acetate and PDA vary by compounder, but most pharmacies treat them as roughly interchangeable on a microgram-per-microgram basis. Independent pharmacokinetic comparison studies are limited.
How long is reconstituted BPC-157 stable?
Reconstituted BPC-157 is generally considered stable for 4 to 8 weeks when stored at 2 to 8 °C and protected from light. The bacteriostatic-water vehicle (benzyl alcohol preservative) is what defines that window; sterile water reconstitution shortens it considerably. Lyophilized powder before reconstitution typically carries an 18- to 24-month shelf life refrigerated. Always defer to the specific stability window printed on your compounding-pharmacy vial.
Compare

BPC-157 head-to-heads

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.